Tagomics Partners with Agilent Technologies to Revolutionize Multiomic Biomarker Discovery

Bio-Techne Partners with Leader Life Sciences to Expand in the GCC Region

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

Home
/
update
/
details

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

NextEdge Admin

20 Nov 2024

2 min 38 sec

The Michael J. Fox Foundation,Biomarker,Parkinson’s Disease

Alamar Biosciences, a leader in precision proteomics, has announced a strategic collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance biomarker discovery and deepen understanding of Parkinson’s disease (PD). This partnership aims to address the urgent need for robust biological classification of PD and related neurodegenerative disorders.

Utilizing Alamar’s advanced proteomics platform, the collaboration will expand the NULISAseq™ CNS Disease Panel 120 to include additional PD-relevant targets. Additionally, MJFF will use Alamar’s high-sensitivity NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to analyze approximately 5,000 samples from its landmark Parkinson’s Progression Markers Initiative (PPMI). Since its launch in 2010, PPMI has created the most comprehensive dataset and biosample library in Parkinson’s research.

“This partnership with MJFF offers a unique opportunity to leverage our NULISAseq™ technology for groundbreaking insights into disease mechanisms,” said Yuling Luo, Founder and CEO of Alamar Biosciences. “Our goal is to accelerate the development of targeted therapies and improve outcomes for patients.”

By applying Alamar’s multiplexed protein detection technology, the collaboration seeks to identify novel biomarkers for early diagnosis, disease tracking, and next-generation treatments.

“MJFF is committed to advancing research to address the critical unmet needs of Parkinson’s patients,” said Nicole K. Polinski, PhD, Director of Research Resources at MJFF. “This collaboration aims to support the development of urgently needed diagnostic and therapeutic tools.”

With its unparalleled dataset, PPMI has already driven significant breakthroughs in PD biology. Together, Alamar Biosciences and MJFF aim to accelerate progress in PD research, advancing the understanding of neuronal synuclein disease and improving the lives of those impacted by the condition.